How many JAZZ shares were withheld in each tax-related transaction?

Two withholdings occurred: one for 6 Ordinary Shares at $244.0633 per share and another for 737 Ordinary Shares at $241.3899 per share, all on August 31, 2026, to satisfy tax obligations from restricted stock unit vesting.

Jazz Pharma director withholds 743 shares for tax

Q: What insider transaction did JAZZ director Ted W. Love report on August 31, 2026?

He reported that 743 Ordinary Shares were disposed of on August 31, 2026 to cover tax obligations arising from the vesting of previously granted restricted stock units, through share withholding rather than an open-market sale.

Q: Were the JAZZ insider transactions open-market sales?

No. The filing states the shares were sold to satisfy tax obligations from the vesting of restricted stock units, meaning they represent tax-withholding dispositions rather than discretionary open-market sales by the director.

Q: Did the JAZZ Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The document-level indicator shows no Rule 10b5-1 trading plan is reported for these August 31, 2026 tax-withholding transactions related to restricted stock unit vesting.

A Jazz Pharmaceuticals director had 743 shares withheld on August 31, 2026 to cover taxes from restricted stock unit vesting, rather than selling shares in the open market.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Ted W. Love reported dispositions of 743 Ordinary Shares on August 31, 2026. Two separate share withholdings of 6 and 737 shares were used to pay tax obligations triggered by the vesting of previously granted restricted stock units. These were administrative tax-withholding events, not open-market sales, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Tax Withholding: 743 shares

Tax Withholding 2 txns

Insider LOVE TED W

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares ^F1	6	$244.0633	$1K
Tax Withholding	Ordinary Shares ^F1	737	$241.3899	$178K

Holdings After Transaction: Ordinary Shares — 2,389 shares (Direct)

Footnotes (1)

F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Key Figures

Shares withheld for taxes (total): 743 shares First tax-withholding lot: 6 shares at $244.0633 per share Second tax-withholding lot: 737 shares at $241.3899 per share +1 more

4 metrics

Shares withheld for taxes (total) 743 shares Ordinary Shares disposed of on August 31, 2026 to satisfy tax obligations from restricted stock unit vesting

First tax-withholding lot 6 shares at $244.0633 per share Ordinary Shares withheld on August 31, 2026 to pay tax obligations

Second tax-withholding lot 737 shares at $241.3899 per share Ordinary Shares withheld on August 31, 2026 to pay tax obligations

Tax-withholding events reported 2 transactions Both on August 31, 2026, for payment of tax obligations via share withholding

Key Terms

restricted stock units, tax obligations, Ordinary Shares

3 terms

restricted stock units financial

"arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares sold to satisfy tax obligations arising out of the vesting"

Ordinary Shares financial

"All reported transactions involved Ordinary Shares of Jazz Pharmaceuticals plc"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What insider transaction did JAZZ director Ted W. Love report on August 31, 2026?

He reported that 743 Ordinary Shares were disposed of on August 31, 2026 to cover tax obligations arising from the vesting of previously granted restricted stock units, through share withholding rather than an open-market sale.

Were the JAZZ insider transactions open-market sales?

No. The filing states the shares were sold to satisfy tax obligations from the vesting of restricted stock units, meaning they represent tax-withholding dispositions rather than discretionary open-market sales by the director.

Did the JAZZ Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The document-level indicator shows no Rule 10b5-1 trading plan is reported for these August 31, 2026 tax-withholding transactions related to restricted stock unit vesting.

What type of security was involved in the JAZZ insider’s Form 4?

All reported transactions involved Ordinary Shares of Jazz Pharmaceuticals plc that were withheld to cover tax obligations associated with the vesting of previously granted restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/02/2026 - 05:30 PM Accepted by SEC EDGAR 09/02/2026 - 05:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOVE TED W

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/31/2026		F⁽¹⁾		6	D	$244.0633	3,126	D
Ordinary Shares	08/31/2026		F⁽¹⁾		737	D	$241.3899	2,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

	By: /s/Paz Dizon, as attorney in fact For: Ted W. Love	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR